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What is the normal value of the 
neutrophil-to-lymphocyte ratio?
Patrice Forget1,4*†, Céline Khalifa1†, Jean‑Philippe Defour2, Dominique Latinne2, Marie‑Cécile Van Pel3 
and Marc De Kock1
Abstract 
Background: Neutrophil‑to‑lymphocyte ratio (NLR) has proven its prognostic value in cardiovascular diseases, infec‑
tions, inflammatory diseases and in several types of cancers. However, no cut‑off has been proposed on the basis of 
reference values coming from healthy population.
Methods: Routine blood samples were obtained (n = 413) from workers (age: median 38, range: 21–66 years) 
involved in a health care prevention program, to determine means, standard deviations (SDs), 95% confidence inter‑
vals (95% CI), percentiles P2.5 and P97.5. A second independent sample of healthy volunteers is compared (n = 29).
Results: The mean NLR is 1.65 [±1.96 SD: 0.78–3.53] (95% CI [0.75–0.81] and [3.40–3.66]). In the second cohort 
(healthy control), the NLR values are in the same range, whichever the used analyzer. No NLR assessed in the valida‑
tion series is out of the proposed limits.
Conclusions: We have identified that the normal NLR values in an adult, non‑geriatric, population in good health are 
between 0.78 and 3.53. These data will help to define the normal values of the NLR.
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Background
Neutrophil-to-lymphocyte ratio (NLR) is a simple 
parameter to assess easily the inflammatory status of a 
subject. It has proven its usefulness in the stratification 
of mortality in major cardiac events [1, 2], as a strong 
prognostic factor in several types of cancers [3–10], or as 
a predictor and a marker of inflammatory or infectious 
pathologies (such is pediatric appendicitis) and postop-
erative complications [11, 12].
However, which NLR value is correlated with a higher 
risk for these patients? Which cut-off value, for the NLR, 
will discriminate normal from abnormal results?
Different values of NLR, with different methods, in 
different populations (cancerous or not) are cited in the 
literature. And finally, no universal value is currently 
available. Therefore, there is a need for reference values 
to progress in the use of this marker.
The aim of this study is to determine the limits of the 
values of the NLR that are observed in an adult, non-geri-
atric population, without any acute illness and/or chronic 
debilitating disease.
Methods
Subjects and data collection
With the agreement of the Ethical Committee (ref. 
2014/451, Chairperson: Prof. Jean-Marie Maloteaux, av. 
Hippocrate, 55-14, 1200 Brussels), we performed the 
following analyses. Blood samples for routine control 
between October 2011 and 2012 were identified from 413 
participants of the health care prevention program for 
workers. Considering the analysis as retrospective, given 
the fact that the samples were pre-collected and treated 
anonymously, the Ethical Committee gave a waiver for 
individual consent. Consequently, no written informed 
consent for participation in the study was obtained from 
participants.
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Median age was 38  years (range: 21–66  years). Typi-
cally, these subjects were in good health, permitting a full 
time job without restriction, and without any active dis-
ease, including cancer and infectious disease and are rep-
resentative of the population as a whole. Blood samples 
were obtained for routine hematologic control in workers 
potentially exposed to X-rays or any others ionizing radi-
ation. Samples were treated anonymously, including sex 
and date of birth. No information was therefore available 
about habits (e.g. tobacco use) and possible comorbidities 
(e.g. obesity or vascular disease).
Normal controls
Our goal is to identify the higher boundary observed 
in a population in good health, but not excluding non-
debilitating disease, tobacco use or oral contraception. 
Therefore, it would be important to compare the results 
to those obtained in a second, and independent, sample 
(n = 29) of normal controls, strictly selected on the basis 
of perfect health, coming from an historical cohort. This 
cohort was used during the process of the calibration of 
the blood analyser. The subjects in this second cohort 
were in the same range of age, but, after interrogation 
and examination, carefully selected on the basis of the 
absence of any chronic disease or substance/medications 
(abuse, including tobacco use).
Samples analyses
Anticoagulated whole blood from routine controls were 
processed on Sysmex XE2100 [TOA Medical Electronics, 
Kobe, Japan], Normal controls were analysed on Sysmex 
XN2000 (TOA Medical electronics Co, Kobe, Japan), 
Advia 2120 (Bayer Diagnostics, Tarritown, NY, USA), 
DXH800 (Beckman Coulter, Miami, FL USA), Cell-Dyn 
Sapphire (Abbott Diagnostics Santa Clara, CA, USA) for 
the determination of the complete blood cell counts and 
differential counts of leukocytes. The absolute neutrophil 
count was divided by the absolute lymphocyte count to 
calculate the NLR.
Statistical analyses
For the statistical analyses, laboratory parameters fit a 
log-normal distribution. Logarithmic conversion was 
therefore used for calculating means and 95% confidence 
limits (95% CI) are presented as arithmetic mean ± 1.96 
SD (with their 95% CI). Power analysis shows that, to test 
the hypothesis that <2.5% of the normal controls would 
be out of the proposed limits, 28 subjects are needed. It 
is the reason why we included 29 blood samples of the 
historical cohort for the external validation.
All the analyses were performed with STATISTICA 
(data analysis software system, version 7, Statsoft Inc. 
2004, Tulsa).
Results
Results coming from the blood samples of the 413 sub-
jects of the main cohort are presented in Table 1. Briefly, 
the mean NLR is 1.65 [±1.96 SD: 0.78–3.53] (95% CI 
[0.75–0.81] and [3.40–3.66]). In the second cohort 
(healthy control), the NLR values are in the same range, 
whichever the used analyzer (Table 1). Consequently, no 
NLR assessed in the validation series is out of the pro-
posed limits.
NLR sample stability over 48 h was assessed; there was 
no significant variation over this time period and the 
NLR was then considered stable.
Discussion
We show here that the NLR values, in a sample of 413 
active subjects in good health, are between 0.78 and 3.58. 
We confirm that no normal control (selected on the basis 
of the absence of any comorbidities and substance abuse, 
including tobacco) exceeded this range.
There are a lot of examples in the literature of the 
interest of the NLR as an independent prognostic fac-
tor of morbidity and mortality in several conditions, 
such as cancers and cardiovascular diseases. NLR is also 
useful in the prediction and the detection of inflamma-
tory and infectious conditions, and their postoperative 
Table 1 Neutrophil-to-lymphocyte ratios obtained in two cohort of subjects (n = 413 and n = 29) on five blood analysers, 
expressed in mean, SD and lower/upper limits of the mean ± 1.96 SD range (and their 95% CI)
Mean SD Lower limit 95% CI Upper limit 95% CI
Initial cohort (n = 413)
 Sysmex XE2100 1.65 1.47 0.78 0.75 0.81 3.53 3.40 3.66
Control cohort (n = 29)
 Beckman DXH800 1.76 1.42 0.89 0.78 1.02 3.49 3.06 3.97
 Siemens 2120i 1.86 1.39 0.97 0.86 1.10 3.54 3.13 4.00
 Abbott SAPHYR 1.68 1.42 0.85 0.74 0.96 3.32 2.92 3.79
 Sysmex XN2000 1.69 1.37 0.91 0.81 1.03 3.12 2.77 3.52
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complications [11, 12]. Nevertheless, none of these stud-
ies based their cut-off on data coming from population in 
good health, and none on data coming from normal con-
trols. Some of these studies chose their cut-off value on 
the basis of the median, higher quartile or values deter-
mined by the use of receiver-operating curves (to predict 
the occurrence of a condition, e.g. cancer recurrence of 
infection) [13–15].
In contrast with these studies, we found here limits 
based on a sample of an active adult population in good 
health.
This value can be used as a cut-off to differentiate 
patients that are in the range of a population in good 
health or not  [16]. Can it be used in other populations 
that this from which this sample is coming? Age is cer-
tainly a limit, as we tested only adult, non-geriatric, sub-
jects (between 21 and 66  years). Additionally, we did 
not have the complete documentation of substance use/
abuse, like tobacco or oral contraceptive. Ethnic group 
origins, sex and season of assessment have not been 
included in the analyses. However, in the sample of nor-
mal control, we see that the 95% CI permits to say that it 
is very improbable that normal controls will have a NLR 
value of 3.5. Nevertheless, it seems logical to interpret 
cautiously this type of parameter (like any other), in a 
clinical context to adjust the interpretation, even if based 
on data coming from a comparable population (Addi-
tional file 1).
Conclusions
We have identified that normal NLR values in an adult, 
non-geriatric, population in good health are between 0.78 
and 3.53. These data may help the researcher as the clini-
cian searching for a cut-off for the NLR, until now lacking.
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